Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Frederich

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Clinical Cardiology|June 15, 2021
Kidney outcomes using a sustained ≥40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trialsDavid Z I Cherney, Samuel Dagogo-Jack, Darren K McGuire, et al.
Sleep & Breathing = Schlaf & Atmung|May 20, 2022
Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trialBrian S Wojeck, Silvio E Inzucchi, Ian J Neeland, et al.
Clinical Journal of the American Society of Nephrology : CJASN|September 9, 2021
Ertugliflozin and Slope of Chronic eGFR: Prespecified Analyses from the Randomized VERTIS CV TrialDavid Z I Cherney, Francesco Cosentino, Samuel Dagogo-Jack, et al.
Diabetologia|March 5, 2021
Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trialDavid Z I Cherney, Bernard Charbonnel, Francesco Cosentino, et al.
Kidney International Reports|April 18, 2023
Effects of Ertugliflozin on Kidney Outcomes in Patients With Heart Failure at Baseline in the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes (VERTIS CV) TrialDavid Z I Cherney, Francesco Cosentino, Darren K McGuire, et al.
BMJ Open Diabetes Research & Care|October 8, 2021
Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trialSamuel Dagogo-Jack, Richard E Pratley, David Z I Cherney, et al.
Diabetes, Obesity & Metabolism|December 19, 2024
Long-term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trialFrancesco Cosentino, Samuel Dagogo-Jack, Robert Frederich, et al.
Diabetes, Obesity & Metabolism|November 17, 2022
Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozinKaren D Corbin, Samuel Dagogo-Jack, Christopher P Cannon, et al.
Kidney Diseases (Basel, Switzerland)|March 3, 2025
Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV TrialDavid Z I Cherney, Robert Frederich, Richard E Pratley, et al.
Diabetes, Obesity & Metabolism|October 17, 2024
Evaluation of an oral small-molecule glucagon-like peptide-1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose-ranging, phase 2, randomized, placebo-controlled studyNeeta B Amin, Robert Frederich, Nikolaos Tsamandouras, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Clinical Cardiology|June 15, 2021
Kidney outcomes using a sustained ≥40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trialsDavid Z I Cherney, Samuel Dagogo-Jack, Darren K McGuire, et al.
Sleep & Breathing = Schlaf & Atmung|May 20, 2022
Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trialBrian S Wojeck, Silvio E Inzucchi, Ian J Neeland, et al.
Clinical Journal of the American Society of Nephrology : CJASN|September 9, 2021
Ertugliflozin and Slope of Chronic eGFR: Prespecified Analyses from the Randomized VERTIS CV TrialDavid Z I Cherney, Francesco Cosentino, Samuel Dagogo-Jack, et al.
Diabetologia|March 5, 2021
Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trialDavid Z I Cherney, Bernard Charbonnel, Francesco Cosentino, et al.
Kidney International Reports|April 18, 2023
Effects of Ertugliflozin on Kidney Outcomes in Patients With Heart Failure at Baseline in the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes (VERTIS CV) TrialDavid Z I Cherney, Francesco Cosentino, Darren K McGuire, et al.
BMJ Open Diabetes Research & Care|October 8, 2021
Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trialSamuel Dagogo-Jack, Richard E Pratley, David Z I Cherney, et al.
Diabetes, Obesity & Metabolism|December 19, 2024
Long-term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trialFrancesco Cosentino, Samuel Dagogo-Jack, Robert Frederich, et al.
Diabetes, Obesity & Metabolism|November 17, 2022
Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozinKaren D Corbin, Samuel Dagogo-Jack, Christopher P Cannon, et al.
Kidney Diseases (Basel, Switzerland)|March 3, 2025
Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV TrialDavid Z I Cherney, Robert Frederich, Richard E Pratley, et al.
Diabetes, Obesity & Metabolism|October 17, 2024
Evaluation of an oral small-molecule glucagon-like peptide-1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose-ranging, phase 2, randomized, placebo-controlled studyNeeta B Amin, Robert Frederich, Nikolaos Tsamandouras, et al.
Pageof 4